| New oral sorbent targeting hyperkalemia; trial results to be presented at ASN. |
|
| ZSPHARMA: Presentation: ZS 9, a Novel, First in Class Hyperkalemia Therapy: Results from a Multicenter, Double Blind, Placebo Controlled, Multiple Dose Study to Evaluate the Effects of ZS 9 in Patients with Chronic Kidney Disease and Hyperkalemia. Presenter: Principal investigator Dr. Stephen R. Ash of Indiana University. |